support_agent

Your contact persons

CHEPLAPHARM Arzneimittel GmbH

View:
format_list_bulleted grid_view

06/01/2026

Martin Krämer becomes new Chief Financial Officer at CHEPLAPHARM
Press releases
Read more chevron_right

05/18/2026

CHEPLAPHARM aligns management board for next phase of growth
Press releases
Read more chevron_right

04/29/2026

CHEPLAPHARM reports revenue growth in the 2025 financial year
Press releases
Read more chevron_right

03/31/2026

CHEPLAPHARM implements new supply chain for manufacturing of Zyprexa®-tablets
Press releases
Read more chevron_right

02/09/2026

Satisfaction Notice of Redemption of EUR Notes
Press releases
Read more chevron_right

02/09/2026

Satisfaction Notice of Redemption of USD Notes
Press releases
Read more chevron_right

02/02/2026

Successful Refinancing: CHEPLAPHARM'S new 6.750% Bond multiple times oversubscribed
Press releases
Read more chevron_right

01/28/2026

Notice of Conditional Full Redemption of USD Notes
Press releases
Read more chevron_right

01/28/2026

Notice of Conditional Full Redemption of EUR Notes
Press releases
Read more chevron_right

01/27/2026

CHEPLAPHARM Arzneimittel GmbH Announces Pricing of €950,000,000 6.750% Senior Secured Notes due 2032
Press releases
Read more chevron_right
Back to top expand_less